Search STOK
Stoke Therapeutics, Inc.
Nasdaq · CIK 1623526
Last close25.62
Daily change-0.39 (-1.50%)
10 Years gain+0.20%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
STOK · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
31.7Momentum
0.0Acceleration
0.0Confidence
63.0Annual Revenue4
Quarterly Revenue14
Annual CFO8
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth13.2 / 25
Quality12.5 / 25
Capital Efficiency0.0 / 20
Balance Sheet6.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Net debt reductionNet debt declined versus the comparison period.
Warnings
Operating margin compression · MEDIUMOperating margin compressed by 486.6953 percentage points.
Heavy share dilution · HIGHDiluted share count increased 11.1439%.
Low interest coverage · HIGHInterest coverage is -4113.8696x.
ROIC declining · MEDIUMROIC declined by 113.4342 percentage points.
Key Metrics
Revenue Growth TTM-76.81%OK
Revenue CAGR 3Y145.89%OK
Gross Margin100%OK
Operating Margin-473.06%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-93.35%OK
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y11.14%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $184.42M | $184.42M | -$20.59M | $45.59M | $44.92M | 100% | -11.16% | 24.35% | -40.71% | 59.22M |
| 2025 FY Dec 31, 2024 | $36.56M | $36.56M | -$101.37M | -$86.85M | -$87.05M | 100% | -277.31% | -238.15% | n/a | 54.01M |
| 2024 FY Dec 31, 2023 | $8.78M | $8.78M | -$114.77M | -$81.07M | -$82.68M | 100% | -1,307.21% | -941.72% | n/a | 43.99M |
| 2023 FY Dec 31, 2022 | $12.41M | $12.41M | -$104.36M | -$31.87M | -$35.83M | 100% | -841.24% | -288.82% | n/a | 38.9M |
| 2022 FY Dec 31, 2021 | n/a | $0.00 | -$86.07M | -$66.91M | -$68.11M | n/a | n/a | n/a | n/a | 36.74M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $40.00M | sum latest 4 fiscal quarters Revenue | OK | 0001193125-26-330557, 0001193125-25-264720 |
| Revenue Growth TTM | -76.81% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001193125-26-330557, 0001193125-25-264720 |
| Revenue CAGR 3Y | 145.89% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-108362 |
| Revenue CAGR 5Y | n/a | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | INSUFFICIENT_HISTORY | 0001193125-26-108362 |
| Gross Profit CAGR 3Y | 145.89% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-108362 |
| Operating Income Growth | -904.48% | OperatingIncome_current / OperatingIncome_prior_year - 1 | OK | 0001193125-26-330557, 0001193125-25-264720 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 100% | Gross Profit / Revenue | OK | 0001193125-26-330557, 0001193125-25-264720 |
| Operating Margin | -473.06% | Operating Income / Revenue | OK | 0001193125-26-330557, 0001193125-25-264720 |
| ROIC | -93.35% | NOPAT / Average Invested Capital | OK | 0001193125-26-330557, 0001193125-25-264720 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001193125-26-330557 |
| Interest Coverage | -4,113.87x | Operating Income / abs(Interest Expense) | OK | derived |
| Current Ratio | 7.69x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $0.61 | Revenue / Diluted Shares | OK | 0001193125-26-330557, 0001193125-25-264720 |